CD30 Ligand (CD30L)-Expressing Acute Myeloid Leukemias: A New Model of Paracrine Interactions for the Regulation of Blast Cells Proliferation

References

• Smith C. A., Gnss H. -J., Davis T., Anderson D., Farrah T., Baker E., Sutherland G. R., Brannan C. I., Copeland N. G., Jenkins N. A., Grabstein K. A., Gliniak B., McAlister I., Fanslow W., Alderson M., Falk M., Gimpcl S., Gillis S., Din W. S., Goodwin R. G., Armitage R. J. CD30 antigen, a marker for Hodgkin's lymphoma is a receptor whose ligand defines an emerging family of cytokinw with homol-ogy to TNF. Cell 1993; 73: 1349–1360
   PubMed Web of Science ®Google Scholar
• Armitage R. J. Tbmor necrosis factor receptor super-family members and their ligands. Current Opinion in Immunology 1994; 6: 407–413
   PubMed Web of Science ®Google Scholar
• Gruss H. -J., Dower S. K. TNF ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85: 3378–3404
   PubMed Web of Science ®Google Scholar
• Anderson D. M., Maraskovsky E., Billingsley W. L., Dou-Gall W. C., Tometsko M. E., Roux E. R., Teepe M. C., DuBose R. F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175–179
   PubMed Web of Science ®Google Scholar
• Wiley S. R., Schooley K., Smolak P. G., Din W. S., Huang C. P., Micholl J. K., Sutherland G. R., Smith T. D., Rauch C., Smith C. A., Goodwin R. G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–682
   PubMed Web of Science ®Google Scholar
• Degli-Espsti M. A., Smolak P. J., Walczak H., Waugh J., Huang C. P., DuBose R. F., Goodwin R. G., Smith C. A. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. Journal of Experimental Medicine. 1997; 186: 1165–1170
   PubMed Web of Science ®Google Scholar
• Gattei V., Degan M., Gloghini A., De Iuliis A., Improta S., Rossi F. M., Aldinucci D., Perin V., Semaino D., Babare R., Zagonel V., Gruss H. -J., Carbone A., Pinto A. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997; 89: 2048–2059
   PubMed Web of Science ®Google Scholar
• Gnss H. -J., Hemnann F. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control for CD30+ lymphoid and lymphoma cells. Leukemia and Lymphoma 1996; 20: 397–409
   PubMed Web of Science ®Google Scholar
• Dürkop H., Lam U., Hummel M., Eithelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68: 421–427
   PubMed Web of Science ®Google Scholar
• Falini B., Pileri S., Pizzolo G., Durkop H., Flenghi L., Stirpe F., Martelli M. F., Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunother-apy. Blood 1995; 85: 1–14
   PubMed Web of Science ®Google Scholar
• Gruss H. -J., Boiani N., Williams D. E., Armitage R. J., Smith C. A., Goodwin R. G. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83: 2045–2056
   PubMed Web of Science ®Google Scholar
• Gruss H. -J., Da Silva N., Hu Z. -B., Uphoff C. C., Goodwin R. G., Drexler H. G. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia. 1994; 8: 2083–2094
   PubMed Web of Science ®Google Scholar
• Gruss H. -J., Pmto A., Gloghini A., Wehnes E., Wright B., Boiani N., Aldinucci D., Gattei V., Zagonel V., Smith G. A., Kadin M. E., von Schilling C., Goodwin R. G., Hemnann F., Carbone A. CD30 ligand expression in normal, reactive and Hodglan's disease-involved lymph nodes. American Journal of Pathology 1996; 149: 469–481
   PubMed Web of Science ®Google Scholar
• Pinto A., Aldinucci D., Gloghini A., Zagonel V., Degan M., Improta S., Juzbasic S., Todesco M., Perin V., Gattei V., Hemnann F., Gnss H. -J., Carbone A. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996; 88: 3299–3305
   PubMed Web of Science ®Google Scholar
• Gruss HA., Ulrich D., Braddy S., Armitage R., Dower S. K. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. European Journal of Immunology 1995; 25: 2083–2089
   PubMed Web of Science ®Google Scholar
• Gruss H. -J., Scheffrahn I., Hübinger G., Duyster J., Herrmann F. The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Stemberg cells. Leukemia. 1996; 10: 829–835
   PubMed Web of Science ®Google Scholar
• Ellis T. M., Simms P. E., Slivink D. J., Jack H. -M., Fisher R. I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45R0+ T cells. Journal of Immunology 1993; 151: 2380–2389
   PubMed Web of Science ®Google Scholar
• Alzona M., Jack H. -M., Fisher R., Ellis TM. CD30 defines a subset of activated human T cells that produce IFN-y and IL-5 and exhibit enhanced B cell helper activity. Journal of Immunology. 1994; 153: 2861–2867
   PubMed Web of Science ®Google Scholar
• Del Prete G. F., De Carli M., Almerigogna F., Daniel C. K., Delios M. M., Zancuoghi G., Piuolo G., Romagnani S. Preferential expression of CD30 by human CD4+ T-cells producing Th2-type cytokines. FASEB Journal 1995; 9: 81–86
   PubMed Web of Science ®Google Scholar
• Hamann D., Hilkens C. M. U., Grogan J. L., Lens S. M. A., Kapsenberg M. L., Yazdanbakhsh M., van Lier R. A. W. CD30 expression does not discriminate between human Th1– and Th2-type T cells. Journal of Immunology 1996; 156: 1387–1391
   PubMed Web of Science ®Google Scholar
• Gattei V., Degan M., De Iuliis A., Rossi M. E., Aldinucci D., Pinto A. Competitive reverse transcriptase PCR: a useful alternative to Northern blotting for quantitative estimation of relative abundances of specific mRNAs in precious samples. Biochemical Journal 1997; 325: 565–567
   PubMed Web of Science ®Google Scholar
• Rothe G., Schmitz G. Consensus protocol for the flow cytometry immunophenotyping of hematopoietic malignancies. Leukemia 1996; 10: 877–895, for the working group on flow cytometry and image analysis
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Rigo A., Zanotti R., Vinante F., Vincenzi C., Cassatella M., Carra G., Castaman G., Chilosi M., Semenzato G. Alpha (p55) and beta (p75) chains of the interleukin-2 receptor are expressed by AML blasts. Leukemia 1993; 7: 418–425
   PubMed Web of Science ®Google Scholar
• Bradstock K. F., Gottlieb D. J. Interaction of acute leukemia cells with the bone marrow microenvironment: Implications for control of minimal residual disease. Leukemia and Lymphoma 1995; 18: 1–16
   PubMed Web of Science ®Google Scholar
• Allen T. D., Dexter T. M. The essential cells of the hematopoietic microenvironment. Experimental Hematology 1984; 12: 517–521
   PubMed Web of Science ®Google Scholar
• Dorshkind K. Regulation of hematopoiesis by bone marrow stromal cells and their products. Annual Reviews of Immunology 1990; 8: 111–137
   PubMed Web of Science ®Google Scholar
• Manabe A., Gopal Murti K., Coustan-Smith E., Kumagai M., Behm F. G., Raimondi S. C., Campana D. Adhesion-dependent survival of normal and leukemic human B-lymphoblasts on bone mamw stromal cells. Blood 1994; 83: 758–766
   PubMed Web of Science ®Google Scholar
• Del Prete G., Maggi E., Pizzolo G., Romagnani S. CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunology Today 1995; 16: 76–80
   PubMedGoogle Scholar
• McDonald P. P., Cassatella M. A., Bald A., Maggi E., Romagnani S., Gruss H., Pizzolo G. CD30 liga-tion induces nuclear factor-kB activation in human T cell lines. Eumpean Journal of Immunology 1995; 25: 2870–2876
   PubMed Web of Science ®Google Scholar
• Gruss H. -J., Ulrich D., Dower S. K., Hemnann F., Brach M. Activation of Hodgkin cells via the CD30 receptor induces autccrine secretion of interleukin-6 engaging the NF-kB transcription factor. Blood 1996; 87: 2443–2449
   PubMed Web of Science ®Google Scholar
• Amakawa R., Hakem A., Kundig T. M., Matsuyama T., Simard J. J. L., Timms E., Wakeham A., Mittruecker H. -W., Griesser H., Takimoto H., Schmits R., Shahinian A., Ohashi P. S., Penniger J. M., Mak T. W. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996; 84: 551–562
   PubMed Web of Science ®Google Scholar
• Lee S. Y., Park C. G., Choi Y. T cell meptordependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. Journal of Experimental Medicine 1996; 183: 669–674
   PubMed Web of Science ®Google Scholar
• Mosmann T. R., Sad S. The expanding universe of T-cell subsets: Thl, Th2 and more. Immunology Today 1996; 17: 138–146
   PubMedGoogle Scholar
• Bowen M. A., Lee R. K., Miragliotta G., Nam S. Y., Podack E. R. Structure and expression of murine CD30 and its role in cytokine production. Journal of Immunology 1996; 156: 442–449
   PubMed Web of Science ®Google Scholar
• Romagnani S. The Th1/Th2 paradigm. Immunology Today 1997; 18: 263–266
   PubMedGoogle Scholar
• Hone R., Ito K., Tatewaki M., Nagai M., Aizawa S., Higashihara M., Ishida T., Inoue J., Takizawa H., Watanabe T. A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. Blood 1996; 88: 2422–2432
   PubMed Web of Science ®Google Scholar
• Hone R., Gattei V., Ito K., Imajo-Ohmi S., Tange T., Miyauchi J., Pinto A., Degan M., De Iuliis A., Higashihara M., Watanabe T. Frequent expression of the variant CD30 (CD30v) in human hematopoietic neoplastic cells, (submitted)
   Google Scholar
• Gruss H. -J., Hermann F., Gattei V., Gloghini A, Pinto A., Carbone A. CD40/CD40 ligand interactions in normal. reactive and malignant lympho-hematopoietic tissues. Leukemia and Lymphoma 1997; 24: 393–422
   PubMed Web of Science ®Google Scholar
• Banchereau J., Bazan F., Blanchard D., Briere F., Galizzi J. P., van Kooten Liu. Y. J., Rousset F., Saeland S. The CD40 antigen and its ligand. Annual Reviews of Immunology 1994; 12: 881–922
   PubMed Web of Science ®Google Scholar
• Alderson M. R., Armitage R. J., Tough T. W., Strockbine L., Fanslow W. C., Spriggs M. K. CD40 expression by human rnonocytes: Regulation by cytokines and activation of monocytes by the ligand for CD40. Journal of Experimental Medicine 1993; 178: 669–674
   PubMed Web of Science ®Google Scholar
• Kiener P. A., Moran-Davis P., Rankin B. M., Wahl A. F., Aruffo A., Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. Journal of Immunology 1995; 155: 4917–4925
   PubMed Web of Science ®Google Scholar
• Vyth-Heese F. A., Dellemijn T. A., Majoor D., de Jong D. Localization in situ of the co-stirnulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lym-phoid tissue. Eumpean Journal of Immunology 1995; 25: 3023–3029
   PubMed Web of Science ®Google Scholar
• Carbone A., Gloghmi A., Gattei V., Aldinucci D., Degan M., Dc Paoli P., Zagonel V., Pinto A. Expression of functional CD40 antigen on Reed-Stemberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780–789
   PubMed Web of Science ®Google Scholar
• Armitage R. J., Fanslow W. C., Strockbine L., Sato T. A., Clifford K. N., Macduff B. M., Anderson D. M., Gimpel S. D., Davis-Smith T., Maliszewski C. R., Fanslow W. C. Molecular and biological characterization of a murine ligand for CD40. Natun 1992; 357: 80–82
   PubMed Web of Science ®Google Scholar
• Spriggs M. K., Armitage R. J., Strockbine L., Clifford K. N., Macduff B. M., Sato T. A., Maliszewski C. R., Fanslow W. C. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. Journal of Experimental. Medicine 1992; 176: 1543–1550
   Web of Science ®Google Scholar
• Clark E. A., Ledbetter J. A. How B and T cells talk to each other. Nature 1994; 367: 425–428
   PubMed Web of Science ®Google Scholar
• Pinto A., Gattei V., Soligo D., Parravicini C., Del Vecchio L. New molecules burst at the leukocyte surface. A comprehensive review based on the 5th International Workshop on Leukocyte Differentiation Antigens. Leukemia. 1994; 8: 347–358
   PubMed Web of Science ®Google Scholar
• Long M. W. Blood cell cytoadhesion molecules. Experimental Hematology 1992; 20: 288–301
   PubMed Web of Science ®Google Scholar
• Russell N. H., Hunter A. E., Bradbury D., Zhu Y. M., Keith F. Biological features of leukemic cells associated with autonomous growth and reduced survival in acute myeloblastic leukemia. Leukemia and Lymphoma 1995; 16: 223–229
   PubMed Web of Science ®Google Scholar
• Schumann R. R., Nakarai T., Gruss H. -J., Brach M., von Amim U., Kirschning C., Karawajew L., Ludwig W. -D., Renauld J., Ritz J., Henmann F. Transcript synthesis and surface expression of the interleukin-2 receptor (α-, b˜-, γ-chain) by normal and malignant myeloid cells. Blood 1996; 87: 2419–2427
   PubMed Web of Science ®Google Scholar
• Nakase K., Kita K., Otsuji A., Anazawa H., Oshino K., Sekine T., Shirakawa S., Tanaka I., Nasu K., Tsutani H., Dohy H., Tsudo M. Diagnostic and clinical importance of interleukin-2 receptor alpha chain expression on non-T-cell acute leukaemia cells. The British Journal of Haematology 1992; 80: 317–326
   PubMed Web of Science ®Google Scholar
• Maio M., Pinto A., Carbone A., Zagonel V., Gloghini A., Marotta G., Cirillo D., Colombatti A., Ferrara F., Del Vecchio L., Ferrone S. Differential expression of CD54/Intercellular adhesion molecule- 1 in myeloid leuke-mias and iymphoproliferative disorders. Blood 1990; 76: 783–790
   PubMed Web of Science ®Google Scholar
• Freedman A. S. Cell surface antigens in leukemias and lymphomas. Cancer Investigation 1996; 14: 252–276
   PubMed Web of Science ®Google Scholar
• Wiley S. R., Goodwin R. G., Smith C. A. Reverse signaling via CD30 ligand. The Journal of Immunology 1996; 157: 3635–3639
   PubMed Web of Science ®Google Scholar
• Bowman M. R., Crimmins M. A. V., Yetz-Aldape J., Kriz R., Kelleher K., Hemnann S. The cloning of CD70 and its identification as the ligand for CD27. The Journal of Immunology 1994; 152: 1756–1761
   PubMed Web of Science ®Google Scholar
• Abbas A. K., Murphy K., Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787–793
   PubMed Web of Science ®Google Scholar
• Coffman R. L., Varkila K., Scott P., Chatelain R. Role of cytokines in the differentiation of CD4 T-cell subsets in vivo. Immunological Reviews 1991; 123: 189–207
   PubMed Web of Science ®Google Scholar
• Romagnani S. Induction of Th1 and Th2 responses: A key role for the “natural” immune response?. Immunol Today 1992; 13: 379–381
   PubMedGoogle Scholar
• Paul W. E., Seder R. A. Lymphocyte responses and cytokines. Cell 1994; 76: 241–251
   PubMed Web of Science ®Google Scholar
• Annunziato F., Manetti R., Tomasevic I., Guidizi M. G., Biagiotti R., Gianno V., Germano P., Mavilia C., Maggi E., Romagnani S. Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production. FASEB Joumul 1996; 10: 769–776
   PubMed Web of Science ®Google Scholar
• Zheng W., Flavell R. A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89: 587–596
   PubMed Web of Science ®Google Scholar
• Zhang D. -H., Yang L., Ray A. Differential responsiveness of the IL-5 and IL-4 genes to transcription factor GATA-3. Journal of Immunology 1998; 161: 3817–3821
   PubMed Web of Science ®Google Scholar
• Ho I. C., Hodge M. R., Rooney J. W., Glimcher L. H. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 1996; 85: 973–983
   PubMed Web of Science ®Google Scholar
• Blank V., Andrews N. C. The Maf transcription factors: regulators of differentiation. Trends in Biological Sciences 1997; 22: 437–441
   PubMed Web of Science ®Google Scholar
• Vellenga E., De Wolf J. Th. M., Beentjes J. A. M., Esselink M. T., Smit J. W., Halie M. R. Divergent effects of IL-4 on the G-CSF and IL-3 supported myeloid colony formation from normal and leukemic bone marrow cells. Blood 1990; 75: 633–637
   PubMed Web of Science ®Google Scholar
• Miyauchi J., Clark S. C., Tsunematsu Y., Shimizy K., Park J. W., Ogawa T., Toyama K. Interleukin-4 as a growth regulator of clonogenic cells in acute myelogenous leukemia in suspension culture. Leukmia 1991; 5: 108–115
   PubMed Web of Science ®Google Scholar
• Akashi K., Harada M., Shibuya T., Eto T., Takamatsu Y., Aoki N. Effects of IL-4 and L-6 on the proliferation of CD34+ and CD34-blasts from acute myelogenous leukemia. Blood 1991; 78: 197–203
   PubMed Web of Science ®Google Scholar
• Imai Y., Nagata K., Suzuki T., Aoki N. Effects of recombinant IL-4 on the growth and differentiation of blast progenitors stimulated with G-CSF, GM-CSF and IL-3 from AML patients. The British Jouml of Haematology 1991; 78: 173–178
   PubMed Web of Science ®Google Scholar
• Tuyt L. M. L., Dokter W. H. A., Esselink M. T., Vellenga E. Divergent effects of IL-10 and IL-4 on the proliferation and growth factor secretion by acte myeloblastic leukemia cells. European Cytokine Network 1995; 6: 231–235
   PubMed Web of Science ®Google Scholar
• Johnston J. A., Kawamura M., Kirken R. A., Chen Y. -Q., Blake T. B., Shibuya K., Ortaldo J. R., McVicar D. W., O'Shea J. J. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994; 370: 151–153
   PubMed Web of Science ®Google Scholar
• Witthuhn B. A., Silvennoien O., Miura O., Lai K. S., Cwik C., Liu E. T., Ihle N. J. Involvement of the Jak-3 Janus kinase in signalling by interleukin 2 and 4 in lymphoid and myeloid cells. Nature 1994; 370: 153–157
   PubMed Web of Science ®Google Scholar
• Hou J., Schindler U., Henzel W. J., Ho T. C., Brasseur M., McKnight S. L. An interleukin-4-induced transcription factor: IL-4 Stat. Science 1994; 265: 1701–1706
   PubMed Web of Science ®Google Scholar
• Wang L. -M., Keegan A. D., Li W., Lienhard G. E., Pacini S., Gutkind J. S., Myers M. G. Jc, Sun X. -J., White M. F., Aaronson S. A., Paul W. E., Pierce J. H. Common elements in interleukin 4 and insulin signaling pathways in factordependent hematopoietic cells. Proceedings of the National Academy of Science of the United Srates of America 1993; 90: 4032–4036
   PubMed Web of Science ®Google Scholar
• Izuhara K., Feldman R. A., Greer P., Harada N. Interaction of the c-fes proto-oncogene product with the interleukind receptor. Jouml of Biological Chemistry 1994; 269: 18623–18629
   PubMed Web of Science ®Google Scholar
• Keegan A. D., Nelms K., White M., Wang L. -M., Pierce J. H., Paul W. E. An IL4 receptor region containing an insulin receptor motif is important for ILQmediated IRS- 1 phosphorylation and cell growth. Cell 1994; 76: 811–820
   PubMed Web of Science ®Google Scholar
• Sun X. J., Wang L. -M., Zhang Y., Yenush L., Meyers M. J., Jr, Lane W. S., Pierce J. H., White M. F. Role of IRS-2 in insulin and cytokine signalling. Nature 1995; 377: 173–177
   PubMed Web of Science ®Google Scholar
• Izuhara K., Feldman R. A., Greer P., Harada N. Interleukin-4 induces association of the c-fes proto-oncogene product with phosphatidylinositol-3 kinase. Blood 1996; 88: 3910–3918
   PubMed Web of Science ®Google Scholar
• Lanfrancone L., Mannoni P., Pebusque M. J., Care A, Peschle C., Grignani F., Pelicci P. Expression pattern of the c-fes oncogene mRNA in human myeloid cells. Intemtional Journal of Cancer 1989; 4%(suppl.)35–38
   Google Scholar
• Hanazono Y., Chiba S., Sasaki K., Mano H., Miyajima A., Arai K. -i., Yazaki Y., Hirai H. c-fps/c-fes protein-tyrosine kinase is implicated in a signaling pathway wiggered by granulocyte-macrophage colony-stimulating factor and L-3. The E. M. B. O. Journl 1993; 12: 1641–1646
   PubMed Web of Science ®Google Scholar
• Banner D. W., D'Arcy A., Janes W., Gentz R., Schanfeld H. -J., Broger C., Lcetscher H., Lesslauer W. Ctystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implication for TNF receptor activation. Cell 1993; 73: 431–445
   PubMed Web of Science ®Google Scholar
• Ishida T., Tojo T., Aoki T., Kobayashi N., Oishi T., Watanabe T., Yamamoto T., Inoue J. TRAF5. a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proceedings of the National Academy of Science of the United States of America 1993; 93: 9437–9442
   Web of Science ®Google Scholar
• Nakano H., Oshima H., Chung W., Williams-Abott L., Ware C. F., Yagita H., Okumura K. TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor. Journal of Biological Chemistry 1996; 271: 14661–14661
   PubMed Web of Science ®Google Scholar
• Aizawa S., Nakano H., Ishida T., Hone R., Nagai M., Ito K., Yagita H., Okumura K., Inoue J., Watanabe T. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TlWF2 are involved in CD30-mediated NF-kB activation. Journal of Biological Chemistry 1997; 272: 2042–2045
   PubMed Web of Science ®Google Scholar
• Lee S. Y., Kandala G., Liou M. -L., Choi Y. CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Proceedings of the National Academy of Science of the United Stares of America 1996; 93: 9699–9703
   PubMed Web of Science ®Google Scholar
• Gedrich R. W., Gilfillan M. C., Ducket C. S., Van Dongen J. L., Thompson CB. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. Journal of Biological Chemistry 1996; 271: 12852–12858
   PubMed Web of Science ®Google Scholar
• Guinan E. C., Gribben J. G., Boussiotis V. A., Freeman G. J., Nadler L. M. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84: 3261–3282
   PubMed Web of Science ®Google Scholar
• Hirst W. J. R., Buggins A., Darling D., Gaken J., Farzaneh F., Mufti G. J. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovi-rus-mediated gene transfer of B7.1. Gene Therapy 1997; 4: 691–699
   PubMed Web of Science ®Google Scholar
• Urban J. L., Schreiber H. Tumor-antigens. Annual Reviews of Immunology 1992; 10: 617–644
   PubMed Web of Science ®Google Scholar
• Boon T., Cerottini J. -C., Van den Eynde B., Van der Bruggen P., Van Pel A. Tumor-antigens recognized by T lymphocytes. Annual Reviews of Immunology 1994; 10: 337–365
   Web of Science ®Google Scholar
• Van Pel A., Van der Bruggen P., Coulie P. G., Brichard V. G., Lethe B., Van den Eynde B., Uyttenhove C., Renauld J. -C., Boon T. Genes coding for tumor-antigens recognized by cytolytic lymphocytes. Immunological Reviews 1995; 145: 229–250
   PubMed Web of Science ®Google Scholar
• Henderson R. A., Finn O. J. Human tumor antigens are ready to fly. Advanced Immunology 1996; 62: 217–256
   PubMed Web of Science ®Google Scholar
• Lee P. P., Zeng D., McCaulay A. E., Chen Y. -F., Geiler C., Umetsu D. T., Chao N. J. T helper 2-dominant anti-lymphoma immune response is associated with fatal outcome. Bood 1997; 90: 1611–1617
   PubMed Web of Science ®Google Scholar